CAMP4 Therapeutics Corporation

CAMP

Healthcare Biotechnology

CAMP4 Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, up 436.5% from fiscal 2024.

Revenue
+138.9%
EPS
+32.7%
Free cash flow
+20.4%

Quarter to September 2026, against a year earlier

4.06 0.34 +9.14%
Market cap
$254.8M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
4/9
ROIC
0.00%
Net debt / EBITDA
2.2×
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '22 Dec '23 Dec '24 Dec '25
Total current assets
84.41 40.01 66.38 114.10
Total non-current assets
18.14 14.93 11.92 3.71
Total Assets
102.55 54.95 78.31 117.81
Total current liabilities
7.95 7.81 9.60 15.51
Total non-current liabilities
10.03 8.72 5.57 54.59
Total liabilities
17.97 16.53 15.16 70.10
Common Equity (Total)
(77.53) (123.73) 63.14 47.70
Shareholders Equity (Total)
84.62 38.42 63.14 47.70
Total Debt
0.15 0.15 0.07 —

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 5 Nov 2026